Seek Returns logo

ALNY vs. AZN: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at ALNY and AZN, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

AZN stands out with 432.07 billion USD in market value—about 11.33× ALNY’s market cap of 38.15 billion USD.

With betas of 0.17 for ALNY and 0.18 for AZN, both show similar volatility profiles relative to the overall market.

AZN is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ALNY, which is purely domestic.

SymbolALNYAZN
Company NameAlnylam Pharmaceuticals, Inc.AstraZeneca PLC
CountryUSGB
SectorHealthcareHealthcare
IndustryBiotechnologyDrug Manufacturers - General
CEODr. Yvonne L. Greenstreet M.B.A., M.D.Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
Price292.58 USD69.68 USD
Market Cap38.15 billion USD432.07 billion USD
Beta0.170.18
ExchangeNASDAQNASDAQ
IPO DateJune 1, 2004May 12, 1993
ADRNoYes

Performance Comparison

This chart compares the performance of ALNY and AZN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ALNY and AZN based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • ALNY posts a negative P/E of -140.68, reflecting last year’s net loss, while AZN at 27.80 signals healthy earnings.
  • ALNY posts a negative forward PEG of -38.16, hinting at anticipated earnings decline, whereas AZN at 2.50 has projections for stable or growing earnings.
  • ALNY has a negative Price-to-Free Cash Flow ratio of -506.05, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, AZN (P/FCF 22.33) indicates positive free cash flow generation.
SymbolALNYAZN
Price-to-Earnings Ratio (P/E, TTM)-140.6827.80
Forward PEG Ratio (TTM)-38.162.50
Price-to-Sales Ratio (P/S, TTM)16.253.93
Price-to-Book Ratio (P/B, TTM)328.685.26
Price-to-Free Cash Flow Ratio (P/FCF, TTM)-506.0522.33
EV-to-EBITDA (TTM)-251.7313.68
EV-to-Sales (TTM)16.374.41
EV-to-Free Cash Flow (TTM)-509.8025.07

Dividend Comparison

ALNY offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while AZN provides a 1.39% dividend yield, giving investors a steady income stream.

SymbolALNYAZN
Dividend Yield (TTM)0.00%1.39%

Financial Strength Metrics Comparison

This section dives into the financial resilience of ALNY and AZN, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • AZN’s current ratio of 0.90 indicates its assets may not cover near-term debts, whereas ALNY at 3.04 maintains healthy liquidity.
  • AZN posts a quick ratio of 0.70, indicating limited coverage of short-term debts from its most liquid assets—while ALNY at 2.98 enjoys stronger liquidity resilience.
  • ALNY is heavily leveraged (debt-to-equity ratio 11.28), which can boost returns but raises risk if borrowing costs climb, while AZN at 0.77 keeps leverage at a more moderate level.
  • With negative EBIT (-0.79), ALNY cannot cover its interest payments. AZN, with an interest coverage of 7.95, meets its interest obligations.
SymbolALNYAZN
Current Ratio (TTM)3.040.90
Quick Ratio (TTM)2.980.70
Debt-to-Equity Ratio (TTM)11.280.77
Debt-to-Assets Ratio (TTM)0.310.30
Interest Coverage Ratio (TTM)-0.797.95